Barry Greene is the Chief Executive Officer and Member of the Board of Directors at Sage Therapeutics. He joined the company in 2020, bringing more than 30 years of biopharmaceutical industry experience to this position. Prior to Sage, Mr. Greene served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003. 

Prior to his 17-year tenure at Alnylam, Mr. Greene was the general manager of oncology at Millennium Pharmaceuticals, Inc. where he led global strategy and execution for its oncology business, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE® (bortezomib) in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as executive vice president and chief business officer for Mediconsult.com, a healthcare consulting company. Earlier in Mr. Greene’s career, he held multiple leadership positions at AstraZeneca (formerly AstraMerck), and was a partner at Andersen Consulting, where he was responsible for the pharmaceutical and biotechnology marketing and sales practice. 

Mr. Greene is a member of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.